Matthew J. Pace

3.8k citations

48 papers · 2.6k · 2 hit papers · h-index 22

Impact in

Virology top 0.5%
- HIV Research and Treatment
Infectious Diseases top 1%
- SARS-CoV-2 and COVID-19 Research
- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- COVID-19 Clinical Research Studies

Papers in

Virology 36
- HIV Research and Treatment 36
Infectious Diseases 21
- HIV/AIDS Research and Interventions 11
- HIV/AIDS drug development and treatment 8
- SARS-CoV-2 and COVID-19 Research 6
- COVID-19 Clinical Research Studies 3

Co-authors: Luis M. Agosto (7 shared papers)Erin H. Graf (7 shared papers)Una O’Doherty (7 shared papers)John Frater (21 shared papers)Una O’Doherty (4 shared papers)Angela M. Mexas (5 shared papers)Jianqing J. Yu (3 shared papers)Frederic D. Bushman (2 shared papers)
Journals: Nature Communications (4 papers)Frontiers in Immunology (3 papers)Virology (3 papers)HIV Medicine (3 papers)AIDS (3 papers)
Partner nations: United Kingdom United States Australia

In The Last Decade

Matthew J. Pace

48 papers receiving 2.6k citations

Matthew J. Pace's Hit Papers

align trajectories log scale

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine 2021 · 249 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2021 Cell
2019 Nature

Peers

Countries citing papers authored by Matthew J. Pace

Since Specialization

Citations

This map shows the geographic impact of Matthew J. Pace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew J. Pace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew J. Pace more than expected).

Fields of papers citing papers by Matthew J. Pace

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew J. Pace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew J. Pace. The network helps show where Matthew J. Pace may publish in the future.

Co-authors

The 25 scholars most cited alongside Matthew J. Pace, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Matthew J. Pace Line = papers co-authored together Matthew J. Pace links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 48 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation Nature ·Ravindra K. Gupta, Sultan Abdul- Jawad, Laura E. McCoy, Hoi Ping Mok, Dimitra Peppa, María Salgado, Javier Martínez‐Picado, Monique Nijhuis Hit paper breakdown →	2019	456
2	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine Cell ·Rebecca Payne, Stephanie Longet, James A. Austin, Donal Skelly, Wanwisa Dejnirattisai, Sandra Adele, Naomi Meardon, Sian E. Faustini Hit paper breakdown →	2021	249
3	Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report The Lancet HIV ·Ravindra K. Gupta, Dimitra Peppa, Alison Lynn Hill, Cristina Gálvez, María Salgado, Matthew J. Pace, Laura E. McCoy, Sarah A. Griffith	2020	174
4	Immunological biomarkers predict HIV-1 viral rebound after treatment interruption Nature Communications ·Jacob M. Hurst, Matthias Hoffmann, Matthew J. Pace, James P. Williams, John Patrick Thornhill, Elizabeth Hamlyn, Jodi Meyerowitz, Kersten K. Koelsch	2015	149
5	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern Nature Communications ·Donal Skelly, Adam C. Harding, Javier Gilbert‐Jaramillo, Michael L. Knight, Stephanie Longet, Anthony Brown, Sandra Adele, Emily Adland	2021	131
6	T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study The Lancet Microbe ·Adrienn Angyal, Stephanie Longet, Shona C. Moore, Rebecca Payne, Adam C. Harding, Tom Tipton, Patpong Rongkard, Mohammad Ali	2021	129
7	Directly Infected Resting CD4+T Cells Can Produce HIV Gag without Spreading Infection in a Model of HIV Latency PLoS Pathogens ·Matthew J. Pace, Erin H. Graf, Luis M. Agosto, Angela M. Mexas, Frances Male, Troy Brady, Frederic D. Bushman, Una O’Doherty	2012	121
8	Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial The Lancet ·Sarah J. Fidler, Wolfgang Stöhr, Matthew J. Pace, Lucy Dorrell, Andrew M. L. Lever, Sarah Lilian Pett, Sabine Kinloch‐de Loes, Julie Fox	2020	109
9	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses Nature Communications ·Ane Ogbe, Barbara Kronsteiner-Dobramysl, Donal Skelly, Matthew J. Pace, Anthony Brown, Emily Adland, Kareena Adair, Hossain Delowar Akhter	2021	104
10	Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection Science Translational Medicine ·Maximilian Muenchhoff, Emily Adland, Owen Karimanzira, Carol E. Crowther, Matthew J. Pace, Anna Csala, Ellen M. Leitman, Angeline Moonsamy	2016	102
11	HIV latency and integration site placement in five cell-based models Retrovirology ·Scott A. Sherrill-Mix, Mary K. Lewinski, Marylinda Famiglietti, Alberto Bosque, Nirav Malani, Karen E. Ocwieja, Charles C. Berry, David J. Looney	2013	98
12	HIV reservoirs and latency models Virology ·Matthew J. Pace, Luis M. Agosto, Erin H. Graf, Una O’Doherty	2011	93
13	Human Immunodeficiency Virus Integrates Directly into Naive Resting CD4+T Cells but Enters Naive Cells Less Efficiently than Memory Cells Journal of Virology ·Jihong Dai, Luis M. Agosto, Clifford Baytop, Jianqing J. Yu, Matthew J. Pace, Megan K. Liszewski, Una O’Doherty	2009	86
14	Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials AIDS ·Angela M. Mexas, Erin H. Graf, Matthew J. Pace, Jianqing J. Yu, Emmanouil Papasavvas, Livio Azzoni, Michael Paul Busch, Michele Di Mascio	2012	81
15	Gag-Positive Reservoir Cells Are Susceptible to HIV-Specific Cytotoxic T Lymphocyte Mediated Clearance In Vitro and Can Be Detected In Vivo PLoS ONE ·Erin H. Graf, Matthew J. Pace, Bennett A. Peterson, Lindsay J. Lynch, Steve B. Chukwulebe, Angela M. Mexas, Farida Shaheen, Jeffrey N. Martin	2013	52
16	Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function PLoS Pathogens ·Matthew J. Pace, James P. Williams, Ayako Kurioka, Andrew B. Gerry, Bent K. Jakobsen, Paul Klenerman, Nneka C. Nwokolo, Julie Fox	2016	47
17	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV JCI Insight ·Ane Ogbe, Matthew J. Pace, Mustapha Bittaye, Timothy Tipoe, Sandra Adele, Jasmini Alagaratnam, Parvinder K. Aley, M. Azim Ansari	2022	36
18	CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA Frontiers in Immunology ·Genevieve Elizabeth Martin, Matthew J. Pace, John Patrick Thornhill, Chansavath Phetsouphanh, Jodi Meyerowitz, Morgane Gossez, Helen L. Brown, Natalia J. Olejniczak	2018	36
19	Patients on HAART often have an excess of unintegrated HIV DNA: Implications for monitoring reservoirs Virology ·Luis M. Agosto, Megan K. Liszewski, Angela M. Mexas, Erin H. Graf, Matthew J. Pace, Jianqing J. Yu, Avinash Bhandoola, Una O’Doherty	2010	30
20	HIV 2-long terminal repeat circular DNA is stable in primary CD4+T Cells Virology ·Matthew J. Pace, Erin H. Graf, Una O’Doherty	2013	30

About Matthew J. Pace

Matthew J. Pace is a scholar working on Virology, Infectious Diseases, Immunology, Emergency Medicine and Modeling and Simulation, having authored 48 papers that have together received 2.6k indexed citations. Recurring topics across this work include HIV Research and Treatment (36 papers), Immune Cell Function and Interaction (15 papers), HIV/AIDS Research and Interventions (11 papers), HIV/AIDS drug development and treatment (8 papers), SARS-CoV-2 and COVID-19 Research (6 papers), T-cell and B-cell Immunology (6 papers), HIV-related health complications and treatments (4 papers) and COVID-19 Clinical Research Studies (3 papers). The work is most often cited by research in Virology (1.4k citations), Infectious Diseases (1.3k citations), Immunology (711 citations), Modeling and Simulation (48 citations) and Health (74 citations). Matthew J. Pace has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Luis M. Agosto, Erin H. Graf, Una O’Doherty, John Frater, Una O’Doherty, Angela M. Mexas, Jianqing J. Yu, Frederic D. Bushman, Sarah J. Fidler and Megan K. Liszewski. Their work appears in journals such as Nature Communications, Frontiers in Immunology, Virology, HIV Medicine and AIDS.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Matthew J. Pace

Impact in

Papers in i

In The Last Decade

Matthew J. Pace

Matthew J. Pace's Hit Papers

Peers

Countries citing papers authored by Matthew J. Pace

Fields of papers citing papers by Matthew J. Pace

All Works

About Matthew J. Pace

Explore authors with similar magnitude of impact

Papers in